Inhibition of the clastogenic effect of cyclophosphamide by WR-2721 in the bone marrow of mice.
The frequency of micronucleated polychromatic erythrocytes in the bone marrow of Swiss mice treated with WR-2721, at a dose of 200 mg/kg or 400 mg/kg body weight, 15 or 30 min prior to cyclophosphamide (CP) administration, at a dose of 200 mg/kg body weight, was determined 24 h after CP treatment. In mice injected with CP, the number of micronuclei in polychromatic erythrocytes was significantly increased in comparison with the controls, and in mice treated with WR-2721 and CP, the frequency of micronucleated polychromatic erythrocytes was distinctly decreased in comparison to those given CP alone. The protective effect of WR-2721 against cyclophosphamide-induced clastogenicity was shown. The effect was dependent on the dose of the thiol agent given, and it was more expressed when WR-2721 was applied at the higher dose, 400 mg/kg body weight. However, the protection by the aminothiol appeared not to depend on the time intervals between WR-2721 and CP administration to the mouse organism.
Mazur
L
L
Department of Animal Physiology, Jagiellonian University, Cracow, Poland.
Czyzewska
A
A
D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects* / Q000473:pathology; D001854:Bone Marrow Cells; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects*; D008297:Male; D051379:Mice; D015162:Micronucleus Tests; D009153:Mutagens / Q000633:toxicity*
D016587:Antimutagenic Agents; D009153:Mutagens; D003520:Cyclophosphamide; D004999:Amifostine